Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Mar 24 2020

Full Issue

Perspectives: Will Americans Actually Be Able To Afford A Vaccine If One Is Available?

Read recent commentaries about drug-cost issues.

The Hill: We Need A Coronavirus Vaccine — I Just Wish We Could Afford It

Since its discovery in Wuhan, China, in December last year, coronavirus has infected more than 100 000 people in 103 countries and resulted in panic, travel bans and quarantines. Talk has turned to a potential vaccine, with President Trump promising one in “a couple of months.” However, Health and Human Services Secretary Alex Azar effectively decided the opposite by stating that the U.S. would not place price controls — regulations to control the cost— on potential coronavirus vaccines. In Azar’s words: “The priority is to get vaccines and therapeutics. Price controls won’t get us there.” (Safura Abdool Karim, 3/20)

Stat: Saving Lives Should Be Good Business. Why Doesn’t That Apply To Finding New Antibiotics?

Ihave spent my career as a biomedical entrepreneur working to develop products that have the potential to save lives while also generating returns for shareholders. Two years ago, I co-founded a new company, Octagon Therapeutics, focused on a critical unmet medical need and a growing market opportunity: more effective antibiotics. It turned out to be a disaster. (Isaac Stoner, 3/18)

Stat: Insulin Prices And PBM Rebates: Pin The Tail On The Patient 

Over the past 15 years, insulin prices have more than doubled. Pharmaceutical companies have been on the receiving end of most of the blame, and the chorus of angry voices has grown louder given Speaker Nancy Pelosi’s H.R. 3 bill, which shows that Americans pay three times more for the same medicines than Europeans do. (Duane Schulthess, 3/19)

The Hill: Congress Needs To Clear A Path For People Living With Diabetes To Stay Safe During Pandemic

While estimates suggest that hundreds of millions of Americans may contract the coronavirus, the complications experienced by those infected will vary widely. The whole point of “flattening the curve” is to ensure that those who are most in need of medical resources — the elderly and those with underlying health conditions — can receive medical attention when they need it. The over 34 million Americans living with diabetes make up a significant part of this group, and we need Congress and the states to provide urgent help to blunt the potentially devastating impact on our community. (Tracey D. Brown, 3/23)

Des Moines Register: Grassley Prescription Drug Bill Holds Big Pharma Accountable

Big Pharma opposes a bill introduced by Sen. Chuck Grassley and supported by Sen. Joni Ernst that would curb rising drug prices, but you wouldn’t know that from a recent  op-ed in the Des Moines Register that calls them pawns of the pharmaceutical industry. The column charged that the Prescription Drug Pricing Reduction Act, which is supported by both Democrats and Republicans, is a giveaway to pharmaceutical companies, falsely claiming that the proposed cap on out-of-pocket costs for Iowans on Medicare wouldn’t “stop corporations” and that the bill is merely paying “lip service” to voters. But what it left out were critical details about the bill, while including irrelevant personal attacks on those who support bipartisan solutions. (Laura Kaminenski, 3/18)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF